A meta-analysis reveals that people with a poor heart failure prognosis stand to gain the most from sodium-glucose cotransporter SGLT2 inhibition, regardless of whether or not they have type 2 diabetes.
An extended-wear insulin infusion set, worn for up to 7 days, is more satisfactory to users than standard insulin infusion sets and does not adversely affect glycemic control, shows a study in people with type 1 diabetes.
The first phase 3 trial of an SGLT2 inhibitor in children and young people with type 2 diabetes shows that dapagliflozin significantly improves their glucose control – as long as they remember to take it.
Being in a minority ethnic group and having low socioeconomic status increase women’s risk for developing certain long-term health complications after a pregnancy affected by gestational diabetes, a study shows.
Moderate- or high-intensity rosuvastatin and high-intensity simvastatin and atorvastatin are the most effective statins for reducing non-high-density lipoprotein cholesterol levels in people with diabetes, study findings indicate.